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 CD14 : a candidate biomarker 
for the prognosis of 
polycystic kidney disease 
 Gregory B.  Vanden Heuvel 1 
 Zhou  et al. validate the expression of markers of the innate immune 
system in the cpk mouse model of polycystic kidney disease (PKD), in 
human recessive PKD, and in human autosomal dominant PKD and show 
that CD14 expression correlates with PKD progression, even from very 
early stages of disease. Moreover, they show that CD14 is expressed from the 
renal tubule epithelial cells, suggesting a mechanism of Toll-like 
receptor-4 activation in PKD prior to the infiltration of inflammatory cells. 
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 Polycystic kidney disease (PKD) is char-
acterized by a disruption in tubular epi-
thelial cells that leads to inappropriate cell 
proliferation, increased fl uid secretion, 
abnormal differentiation, and altered 
extracellular matrix that all contribute to 
the development of numerous renal cysts 
in the kidney. Countless studies have 
focused on the role of cell proliferation, 
fl uid secretion, apoptosis, and extracel-
lular matrix in the progression and patho-
genesis of this devastating disease. 1 Th ese 
studies have led to a better understanding 
of the progression of the disease, and, 
in some cases, to potential therapeutic 
approaches for treating PKD. 2 However, 
patient studies have demonstrated a 
remarkable heterogeneity in the onset and 
progression of the disease, suggesting that 
disease progression is infl uenced by other 
environmental and genetic factors. Recent 
studies have identifi ed the innate immune 
system as one such biological process that 
infl uences the progression of PKD. Mrug 
 et al. 3 showed that severely aff ected cpk 
mice, compared with mildly aff ected cpk 
mice, expressed higher levels of markers 
for alternatively activated macrophages, 
indicative of the innate immune response 
and eff ectors of fi brosis that are associated 
with PKD. 
 Autosomal dominant PKD (ADPKD) 
is characterized by the development of 
numerous renal cysts that slowly progress 
over the lifetime of a patient, resulting 
in end-stage renal disease later in life. 
Traditionally, the measure of glomerular 
filtration rate (GFR) has been used to 
evaluate renal function. By GFR measure-
ments, the disease is largely asymptomatic 
until the third or fourth decade. Soon 
aft er the onset of symptoms, there is a 
rapid decline in GFR, leading to end-
stage renal disease. Recently, a number of 
imaging studies, including the multi-insti-
tutional CRISP (Consortium for Radio-
logic Imaging Studies of Polycystic Kidney 
Disease) study, have provided a mecha-
nism to accurately quantify cystic disease 
progression. 4,5 These studies make it 
increasingly clear that GFR is actually a 
poor predictor of PKD progression. While 
the loss of nephrons in PKD occurs in a 
linear progression, renal function does 
not decline linearly. Rather, renal func-
tion, as measured by GFR, is maintained 
at a fairly normal level, until it reaches a 
threshold at which the small number of 
remaining nephrons can no longer main-
tain a normal function. Aft er reaching 
this threshold, the GFR declines precipi-
tously, leading to end-stage renal disease. 
For the patient, this is viewed as a sudden 
acceleration of the disease, when in 
reality the disease has been progressing all 
along. Moreover, by the time the GFR 
declines, ADPKD has progressed to such 
an extent that the only treatment is trans-
plantation. Any hope, therefore, for the 
treatment of PKD must come long before 
the disease shows symptoms. Since cysts 
are now known to begin during early 
development, perhaps even  in utero , it 
is imperative to be able to measure cyst 
progression long before symptoms 
appear. 4 Th e onset of symptoms means 
that the disease has progressed to the 
point that little normal renal parenchyma 
is left . Any treatments at this stage will 
likely be ineff ective. 
 In a follow-up to Mrug  et al. , 3 Zhou 
 et al. 6 (this issue) validated that a well-
known marker of alternatively activated 
macrophages, CD14, is highly upregulated 
in the kidneys of severely affected cpk 
mice. CD14 is a pattern recognition recep-
tor that facilitates the binding of lipopoly-
saccharides (LPSs) to the Toll-like receptors 
(TLRs) to activate the innate immune sys-
tem. CD14 is expressed at high levels on 
the cell surface of monocytes and macro-
phages, where it is membrane bound by 
glycosyl phosphatidylinositol linkage, and 
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at lower levels in nonmyeloid cells, such as 
liver and kidney. 7 After activation, the 
membrane-bound CD14 can be proteo-
lytically shed. CD14 is also found in a solu-
ble form that confers LPS sensitivity to cells 
that lack membrane-bound CD14. An 
increase of infl ammatory cells is character-
istic of late stages of PKD and is involved in 
the increased fi brosis observed in PKD. 
Zhou  et al. 6 found that rather than being 
expressed by infi ltrating macrophages, the 
source of the elevated CD14 was the cystic 
and non-cystic renal tubular epithelial cells 
( Figure 1 ). Moreover, cpk mice showed 
very high levels of the proteolytically shed 
variant of CD14. Th e elevated soluble CD14 
protein was also observed by immuno-
precipitation of urine from recessive PKD 
patients. Finally, immunoprecipitated 
urine from a small number of ADPKD 
patients showed the presence of soluble 
forms of CD14, which were also elevated 
in cyst fl uid. Th e search for biomarkers for 
PKD has been ongoing. Urinary excretion 
of monocyte chemoattractant protein-1 
(MCP-1) has been shown both in animal 
models of PKD and in ADPKD patients. 8 
However, the expression of MCP-1 is not 
correlative with disease progression until late 
stages of cystogenesis in the cpk mice. Strik-
ingly, CD14 upregulation was signifi cant in 
cpk mice as early as 5 postnatal days and 
increased as the disease progressed. Th e cor-
relation of CD14 levels in the urine of 
ADPKD patients with PKD progression as 
measured by changes in total kidney vol-
ume over a 2-year span suggests that meas-
urement of CD14 in the urine could be a 
biomarker for the early progression of 
ADPKD, making clinical trials feasible. 
 CD14 functions in the innate immune 
system to bind LPSs and, together with 
LPS-binding protein (LBP), to bind and 
activate TLR signaling. One of the TLR 
proteins, TLR4, is expressed throughout the 
nephron, including the proximal tubule and 
collecting duct. 7 Th us, increased CD14 pro-
tein in PKD, shed from renal tubular epi-
thelial cells, could interact with TLR4 in 
the proximal tubule or collecting duct to 
activate signaling. Interestingly,  TLR4 is a 
candidate modifi er gene of cystic kidney 
disease. As Zhou  et al. 6 very nicely describe, 
 TLR4 fulfi lls all of the major modifi er-gene 
criteria established by the Complex Trait 
Community. In addition, TLR4 signaling 
can be activated not only by LPSs, but also 
by heparan sulfate, fi brinogen, and other 
extracellular matrix degradation prod-
ucts. 9,10 In the case of fi brinogen, this acti-
vation can be blocked with anti-CD14 
antibodies. 10 Thus, the elevated CD14, 
in addition to being a biomarker for 
PKD, could be a therapeutic target for the 
treatment of PKD. 
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Activated renal tubule cell
 Figure 1  |  A potential mechanism of TLR4 activation in PKD. Toll-like receptor-4 (TLR4) is 
present on renal epithelial cells, including cells of the proximal tubule and collecting ducts. 
CD14 is expressed at high levels in macrophages and monocytes, and low levels in nonmyeloid 
cells, including cells of the kidney and liver, where it is membrane bound through glycosyl 
phosphatidylinositol linkage. Normally, CD14 facilitates the binding of lipopolysaccharides (LPSs) 
to TLR to activate the innate immune response. However, TLR4 signaling can also be activated by 
interaction with extracellular matrix (ECM) degradation products. In PKD, there is an upregulation 
of CD14 expression and increased levels of the proteolytically shed CD14 variant, indicative of 
immunological activation or cell injury. Thus, the renal tubule-derived CD14 could activate TLR4 
signaling either locally or in more distal segments of the nephron, long before the infiltration of 
inflammatory cells. In addition, proteolytically shed CD14 is found in the urine of both recessive 
PKD and autosomal dominant PKD (ADPKD) patients, where, in the case of ADPKD, the levels 
correlate with PKD progression. Thus, CD14 could be a biomarker for the early progression of 
PKD. Abbreviations: AP-1, activator protein 1; PI3K, phosphatidylinositol-3  -kinase; TNF-  , tumor 
necrosis factor-  . 
